ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation
AuthorsSama, Reddy Ranjith Kumar
McKeon, Jeanne E.
Rotunno, Melissa S.
Landers, John E.
Brady, Scott T.
UMass Chan AffiliationsDepartment of Neurology
Document TypeJournal Article
KeywordsAmyotrophic lateral sclerosis
Mechanisms of disease
Biochemistry, Biophysics, and Structural Biology
Nervous System Diseases
Neuroscience and Neurobiology
MetadataShow full item record
AbstractMutations in Fused in Sarcoma/Translocated in Liposarcoma (FUS) cause familial forms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive axonal degeneration mainly affecting motor neurons. Evidence from transgenic mouse models suggests mutant forms of FUS exert an unknown gain-of-toxic function in motor neurons, but mechanisms underlying this effect remain unknown. Towards this end, we studied the effect of wild type FUS (FUS WT) and three ALS-linked variants (G230C, R521G and R495X) on fast axonal transport (FAT), a cellular process critical for appropriate maintenance of axonal connectivity. All ALS-FUS variants impaired anterograde and retrograde FAT in squid axoplasm, whereas FUS WT had no effect. Misfolding of mutant FUS is implicated in this process, as the molecular chaperone Hsp110 mitigated these toxic effects. Interestingly, mutant FUS-induced impairment of FAT in squid axoplasm and of axonal outgrowth in mammalian primary motor neurons involved aberrant activation of the p38 MAPK pathway, as also reported for ALS-linked forms of Cu, Zn superoxide dismutase (SOD1). Accordingly, increased levels of active p38 MAPK were detected in post-mortem human ALS-FUS brain tissues. These data provide evidence for a novel gain-of-toxic function for ALS-linked FUS involving p38 MAPK activation.
SourceSci Rep. 2017 Mar 8;7(1):115. doi: 10.1038/s41598-017-00091-1. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/40317
RightsCopyright © The Author(s) 2017